Bemiparin sodium

Bemiparin sodium
Clinical data
Trade names	Badyket, Ivor, Hibor, Zibor, others
AHFS/Drugs.com	International Drug Names
Routes of; administration	Subcutaneous injection (except for haemodialysis)
ATC code	B01AB12 (WHO) ;
Pharmacokinetic data
Bioavailability	96% (estimated)
Elimination half-life	5–6 hours
Identifiers
CAS Number	91449-79-5 ;
DrugBank	DB09258 ;
ChemSpider	none;
Chemical and physical data
Molar mass	3600 g/mol (average)
	(what is this?) (verify)

Bemiparin (trade names Ivor and Zibor, among others) is an antithrombotic and belongs to the group of low molecular weight heparins (LMWH).[1]

Medical uses

Bemiparin is used for the prevention of thromboembolism after surgery, and to prevent blood clotting in the extracorporeal circuit in haemodialysis.[2]

Contraindications

The medication is contraindicated in patients with a history of heparin-induced thrombocytopenia with or without disseminated intravascular coagulation; acute bleeding or risk of bleeding; injury or surgery of the central nervous system, eyes or ears; severe liver or pancreas impairment; and acute or subacute bacterial endocarditis.[2]

Interactions

No interaction studies have been conducted. Drugs that are expected to increase the risk of bleeding in combination with bemiparin include other anticoagulants, aspirin and other NSAIDs, antiplatelet drugs, and corticosteroids.[2]

Chemistry

Like semuloparin, bemiparin is classified as an ultra-LMWH because of its low molecular mass of 3600 g/mol on average.[3] (Enoxaparin has 4500 g/mol.) These heparins have lower anti-thrombin activity than classical LMWHs and act mainly on factor Xa, reducing the risk of bleeding.[4]

References

Chapman TM, Goa KL (2003). "Bemiparin: a review of its use in the prevention of venous thromboembolism and treatment of deep vein thrombosis". Drugs. 63 (21): 2357–77. doi:10.2165/00003495-200363210-00009. PMID 14524738.
Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag. 2018. Ivor 2500 IE Anti-Xa/0,2 ml Injektionslösung in Fertigspritzen.
Planès A (September 2003). "Review of bemiparin sodium--a new second-generation low molecular weight heparin and its applications in venous thromboembolism". Expert Opinion on Pharmacotherapy. 4 (9): 1551–61. doi:10.1517/14656566.4.9.1551. PMID 12943485. S2CID 13566575.
Jeske WP, Hoppensteadt D, Gray A, Walenga JM, Cunanan J, Myers L, Fareed J, Bayol A, Rigal H, Viskov C (October 2011). "A common standard is inappropriate for determining the potency of ultra low molecular weight heparins such as semuloparin and bemiparin". Thrombosis Research. 128 (4): 361–7. doi:10.1016/j.thromres.2011.03.001. PMID 21458847.

External links

bemiparin at the U.S. National Library of Medicine Medical Subject Headings (MeSH)

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Chapman TM, Goa KL (2003). "Bemiparin: a review of its use in the prevention of venous thromboembolism and treatment of deep vein thrombosis". Drugs. 63 (21): 2357–77. doi:10.2165/00003495-200363210-00009. PMID 14524738.

[AC-2] Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag. 2018. Ivor 2500 IE Anti-Xa/0,2 ml Injektionslösung in Fertigspritzen.

[3] Planès A (September 2003). "Review of bemiparin sodium--a new second-generation low molecular weight heparin and its applications in venous thromboembolism". Expert Opinion on Pharmacotherapy. 4 (9): 1551–61. doi:10.1517/14656566.4.9.1551. PMID 12943485. S2CID 13566575.

[4] Jeske WP, Hoppensteadt D, Gray A, Walenga JM, Cunanan J, Myers L, Fareed J, Bayol A, Rigal H, Viskov C (October 2011). "A common standard is inappropriate for determining the potency of ultra low molecular weight heparins such as semuloparin and bemiparin". Thrombosis Research. 128 (4): 361–7. doi:10.1016/j.thromres.2011.03.001. PMID 21458847.